

of vitiligo with other autoimmune diseases (4). A defective antioxidant defence is also postulated to lead to the unhindered cytotoxic action of reactive oxygen species such as superoxide anion, hydroxyl radical etc. Once formed these highly reactive free radicals can start a chain reaction and bring about lipid peroxidation producing lipid peroxides and lipoxides, whose further decomposition yields a variety of end products, including malondialdehyde (MDA). These products can cause damage to cell membrane or DNA leading to cytotoxicity, mutagenicity and cell death (5). These reactive oxygen species are generated following ultraviolet rays induced damage to the epidermis and are cytotoxic to melanocytes and also inhibit tyrosinase (6). The presence of autoantibodies to melanocytes and tyrosinase may be a secondary phenomenon to the cytokines released due to the free radical damage. To prevent free radical damage the body has a defense system of antioxidants.

The oxidative stress can either result from increase generation of free radicals or decreased destruction of these. Hence, the antioxidant plays an important role in the free radical mediated damage. The aetiology that suggests that the destruction of melanocytes in vitiligo, induced by increased oxidative stress to activate an autoimmune response seems to be appropriate. But, very few studies are available to support this. Therefore, this study was conducted to find out the balance between level of oxidative stress and antioxidant in 40 patient taking four parameters together.

MATERIAL AND METHODS

This study was undertaken in the

Department of Physiology and Biochemistry, Moti Lal Nehru Medical College, Allahabad from November 2006 to November 2007. Ethical clearance from Ethical Committee of Institute was obtained for this study.

Patients and controls

Forty patients with stable (for at least 2 years) generalized vitiligo (involving greater than 20% body surface area symmetrically) and equal no. of healthy volunteers devoid of any depigmented patch were selected as control group in this study. The patients and controls group had males: females as 1:1 and belong to age group between 11–20 years. Patient group was chosen from Bajaj Skin Clinic and Skin Department, Swaroop Rani Nehru Hospital, Allahabad, India. They had no concomitant dermatological and/or systemic diseases and had not used any systemic or topical treatment at least for a month. There was no history of smoking, long term use of any drugs and were not doing excessive exercise except daily life activities among both the groups.

After obtaining proper consent, blood samples were collected in EDTA vials and antioxidants levels of ceruloplasmin, uric acid, vitamin E and malondialdehyde were analysed according to established methods (7–11). Statistical analyses were done by using Student's 't' test. A 'P' value less than 0.05 was considered as significant.

RESULTS AND DISCUSSION

Our result revealed a significantly higher value of malondialdehyde and lower level of uric acid, ceruloplasmin and vitamin E in

the blood of vitiligo patients as compared to controls. Malondialdehyde was higher by approximately 36% and antioxidants were lower by about 28–38% in comparison to their control. Data are presented in Table I.

Recently, many studies have reported accumulation of free radicals (oxidative stress) in the epidermal layers of the affected skin (12–14) and blood of vitiligo patients (15). Oxidative stress could be an important phenomenon leading to melanocyte death in vitiligo. Damage caused by free radicals could be a possible pathogenic factor for vitiligo (16). In order to evaluate whether the activity of the disease is associated with an oxidative stress, we measured the level of oxidative stress by measuring malondialdehyde level in blood of patients with vitiligo. A measurement of malondialdehyde in the blood provides evidence of lipid peroxidation (17, 18). It is also an indirect method to detect free radical production in human. In our study the levels of malondialdehyde in the blood were found to be higher than the controls ($P < 0.05$; Table I). A higher level of malondialdehyde in tissues and serum in comparison to controls were also reported in previous studies (19, 20). However, only few reports have considered the antioxidants

level along with malondialdehyde that too only enzymatic antioxidants. In this study, we have considered both enzymatic and non-enzymatic antioxidants.

Uric acid has proven to be a selective non-enzymatic and chain breaking antioxidant. It contributes as much as two-thirds of all free radical scavenging capacity in plasma. It serves a protective physiological role by preventing lipid peroxidation (21). In a variety of organs and vascular beds, local uric acid concentration increases during acute oxidative stress and ischaemia, and the increased concentrations might be a compensatory mechanism that confers protection against increased free radical activity (22). In our study level of uric acid was found to be significantly low in vitiligo patients as compared to age matched healthy controls.

Vitamin E is an enzymatic and chain breaking antioxidant and protects molecules and cell membranes in the human body against the destructive effects of oxygen containing free radicals. It plays a key role in the functioning of the immune system. A study showed high level of vitamin E in the vitiligo patient's melanocytes as compared to normal melanocytes when exposed to various concentration of a peroxidizing agent (13). However, other studies did not find significant difference of plasma vitamin E between stable and active vitiligo patients (23, 24). Significant improvement in vitiligo patients receiving antioxidant supplements containing vitamin E was seen in one study (25). In our study we found a significantly low levels of vitamin E in patients with vitiligo as compared to age matched healthy controls.

TABLE I: Malondialdehyde and antioxidants in vitiligo patients blood with age group 11–20 years.

| Particulars | Control Group (n=40) | Patient Group (n=40) |
|---------------------------|-------------------------|-------------------------|
| MDA(μ moles/L) | 2.333 \pm 0.84 | 3.184 \pm 0.87** |
| Vit E(mg/100 ml) | 1.13 \pm 0.57 | 0.7 \pm 0.43* |
| Uric acid(mg/100 ml) | 4.55 \pm 1.15 | 2.74 \pm 0.79** |
| Ceruloplasmin (mg/100 ml) | 36.84 \pm 4.67 | 26.42 \pm 3.51** |

* $P < 0.05$, ** $P < 0.001$ as compared to control group.

Ceruloplasmin is a transport oxidase protein with non enzymatic and preventive antioxidant property (26). A study on the antioxidant status of black patients with vitiligo, found no significant difference in the blood levels of ceruloplasmin. We found a significant difference between ceruloplasmin levels in vitiligo patients and age matched healthy controls (27).

In conclusion, a disturbance in the oxidant-antioxidant system in vitiligo patients' blood was observed in our study. This favours the aetiology that suggests that the destruction of melanocytes in vitiligo

induced by increased oxidative stress and decreased level of antioxidants, activates an autoimmune response. However, the exact mechanism still needs to be analysed.

ACKNOWLEDGEMENTS

The authors are thankful to Dr A. K. Bajaj (Ex-HOD) and Dr Sudha Yadav (Lecturer), Department of Dermatology, Moti Lal Nehru Medical College, Allahabad (U.P) for providing facilities to carry out this work and guidance. We also thank Dr Tandra and Dr Sweta for statistical and technical assistance.

REFERENCES

1. Moshell A. Question and Answers about vitiligo. *NIH Publication* 2001; No. 07, 4909: 1.
2. Kovacs SO, Missouri SF. Vitiligo. *J Am Acad Dermatol* 1998; 38: 647-666.
3. Halder RM. Childhood vitiligo. *Clinics in Dermatology* 1997; 15: 899-906.
4. Onganae K, Van Geel. Evidence for an autoimmune pathogenesis of vitiligo. *Pigment Cell Res* 2003; 16: 90-100.
5. Cross CC, Halliwell B, Borish. Davis conference: oxygen radicals and human disease. *Ann Intern Med* 1987; 107: 536-545.
6. Jaynath DP, Pai BS, Shenoj SD, Balachandran C. Efficacy of antioxidants as an adjunct to photochemotherapy in vitiligo. A case study of 30 patients. *Indian J Dermatol Venereol Leprol* 2002; 68: 202-205.
7. Utley HG, Bernheim F, Hochstein P. Effect of sulfhydryl peroxidation in microsomes. *Arch Biochem Biophys* 1967; 118: 29-32.
8. Henry RJ, Common C, Winkelman JW (eds). *Clinical Chemistry; Principles and techniques*, Harper and Row, Hagerstown, MD, 1974.
9. Fossati P, Prencipe L. Use of 3, 5-dichloro-2-hydroxybenzenesulfonic acid/4-aminophenazone chromogenic system in direct enzymic assay of uric acid in serum and urine. *Clin Chem* 1980; 26: 227-231.
10. Hashim SA, Schuttringer GR. Rapid determination of tocopherol in macro and micro quantities of plasma. *Am J Clin Nutrition* 1996; 19: 137-144.
11. Ravin HA. An improved calorimetric assay of ceruloplasmin. *J Lab Clin Med* 1961; 58: 161-168.
12. Schallreuter KU, Wood JM, Berger J. Low catalase levels in epidermis of patients with vitiligo. *J Invest Dermatol* 1991; 6: 1081-1085.
13. Maresca V, Roccella M, Roccella F, Camera E, Del Porto G. Increased sensitivity to peroxidative agents as a possible pathogenic factor of melanocytic damage in vitiligo. *J Invest Dermatol* 1997; 109: 945-977.
14. Schallreuter KU, Moore J, Wood JM, Beazley WD, Peters EM, Marles LK. Epidermal H₂O₂ accumulation alters tetrahydrobiopterin (6BH₄) recycling in vitiligo: Identification of a general mechanism in regulation of all 6BH₄-dependent processes? *J Invest Dermatol* 2001; 1: 167-174.
15. Hazneci E, Karabulut AB, Ozturk C, Batcioglu K, Dogan G, Karaca S. A comparative study of superoxide dismutase, catalase and glutathione peroxidase activities and nitrate levels of vitiligo patients. *Int J Dermatol* 2005; 44: 636-640.

16. Marks DB, Marks AD, Smith CM. *Oxygen Metabolism and Oxygen Toxicity in Basic Medical Biochemistry: A Clinical Approach*. Baltimore, Williams & Wilkins 1996; 327–340.
17. Taieb A. Intrinsic and extrinsic pathomechanism in vitiligo. *Pigment Cell Res* 2000; 13(suppl.8): 41–47.
18. Draper HH, Hadley M. Malondialdehyde determination as index of lipid peroxidation. *Methods Enzymol* 1990; 186: 421–431.
19. Yildirim M, Baysal V, Inaloz HS, Canth M. The role of oxidants and antioxidants in generalized vitiligo at tissue level. *J Eur Acad Dermatol Venereol* 2004; 18(6): 683–686.
20. Yildirim M, Baysal V, Inaloz HS, Kesici D, Delibas N. The role of oxidants and antioxidants in generalized vitiligo. *J Dermatol* 2003; 30(2): 104–108.
21. Squadrito GL, Cueto R. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. *Arch Biochem Biophys* 2000; 376: 333–337.
22. Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? *Atherosclerosis* 2000; 148: 131–139.
23. Ines D, Sonia B, Riadh BM, Amel el G. A Comparative study of oxidant-antioxidant status in stable and active vitiligo patients. *Arch Dermatol Res* 2006; 298: 141–152.
24. Agrawal D, Shajil EM, Marfatia YS, Begum R. Study on the antioxidant status of vitiligo patients of different age groups in Baroda. *Pigment Cell Res* 2004; 17: 289–294.
25. Dell'Anna ML, Mastrofrancesco A. Antioxidant and narrow band UVB in the treatment of vitiligo: a double-blind placebo controlled trial. *Clin Exp Dermatol* 2007; 32: 631–636.
26. Magalova T, Beoo J. Concentration of Cu, Zn, Se and their relationship to ceruloplasmin and antioxidant enzymes activities. *Bratisl Lek Listy* 1997; 98: 8–11.
27. Boisseau Garsaud P, Lejoly-Boissaeu H, Robert M, Quist D, Arveiler B. Increase in the total antioxidant status and selenium levels in black patients with active vitiligo. *Int J Dermatol* 2002; 10: 640–642.